JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jazz Pharmaceuticals PLC (JAZZ) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the company shows positive financial growth and strong analyst ratings, the lack of immediate trading signals, neutral insider and hedge fund sentiment, and a potential short-term downward trend in stock price suggest waiting for a better entry point. The stock is more suitable for those who can wait for a more favorable price or have a higher risk tolerance.
The technical indicators show a bullish trend with MACD positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the stock trading near its first resistance level (R1: 189.199). However, the RSI is in the neutral zone at 73.706, and the stock has a 40% chance to decline by -1.98% in the next day, -4.12% in the next week, and -9.32% in the next month, indicating potential short-term weakness.
Strong analyst ratings with multiple price target increases, including Piper Sandler's $232 target and BofA's $275 target.
Positive financial growth in Q4 2025 with revenue up 10.09% YoY and EPS up 7.07% YoY.
Collaboration with the American Nutrition Association, which could enhance brand visibility and patient engagement.
Gross margin dropped slightly to 73.01%, down -0.76% YoY.
Neutral insider and hedge fund sentiment with no significant trading trends.
Short-term stock trend analysis suggests potential declines in the next day, week, and month.
In Q4 2025, Jazz Pharmaceuticals reported a 10.09% YoY increase in revenue to $1.197 billion, a 6.45% YoY increase in net income to $203.45 million, and a 7.07% YoY increase in EPS to $3.33. However, the gross margin slightly declined to 73.01%, down -0.76% YoY.
Analysts are highly positive on Jazz Pharmaceuticals, with multiple firms raising price targets. Piper Sandler raised the target to $232, BofA to $275, and Deutsche Bank to $255, all maintaining Buy or Overweight ratings. Analysts highlight strong growth prospects, particularly in oncology and the central nervous system base business, with visibility into double-digit growth starting in 2027.
